Compare ATOS & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATOS | MDBH |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 36.7M |
| IPO Year | 2010 | 2022 |
| Metric | ATOS | MDBH |
|---|---|---|
| Price | $5.43 | $3.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 53.0K | 6.6K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $2.75 |
| 52 Week High | $7.56 | $5.50 |
| Indicator | ATOS | MDBH |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 62.91 |
| Support Level | $0.66 | $3.16 |
| Resistance Level | $5.56 | $3.80 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 50.32 | 61.32 |
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.